-1753359861743.webp&w=3840&q=75)
2025 NOSCM | Optimal Therapy for Early Stage Triple Negative Breast Cancer
0% Complete
Course Overview
Dr. Hope Rugo emphasized neoadjuvant therapy for TNBC and the role of pembrolizumab.
Course Content
This material is non-CME, no credits are available, and a certificate will not be provided upon completion.
Course Details
- Duration
- 0.00 hour
- Released
- Jul 25, 2025
- Last Review
- Jul 25, 2025
- Expires
- Jul 25, 2026
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Faculty & Disclosure
Faculty
Hope S. Rugo, MD, FASCO
Accreditation
NA
Related Courses
2026 NOSCM | We Should Change Treatment Based on Emerging Mutations in Patients with ER+/HER2- Metastatic Breast Cancer (NO)
0.00 Credits
1 Chapter
Breast
Free
2026 NOSCM | We Should Change Treatment Based on Emerging Mutations in Patients with ER+/HER2- Metastatic Breast Cancer (YES)
0.00 Credits
1 Chapter
Breast
Free